ThromboGenics to Present at the Jefferies 2011 Global Life Sciences Conference in New York
LEUVEN, Belgium, June 7, 2011 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that Patrik De Haes, the Chief Executive Officer of ThromboGenics will present an overview of the Company's strategy and key development programs at the Jefferies 2011 Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, U.S. on 8 June 2011 at 8.30am EDT.
The Company's presentation can be accessed via http://www.thrombogenics.com
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative ophthalmic medicines. The Company's lead product ocriplasmin (microplasmin) has completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). Ocriplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.
ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
For further information please contact: ThromboGenics Dr. Patrik De Haes, CEO Tel: +32-16-75-13-10 email@example.com Chris Buyse, CFO Tel: +32-16-75-13-10 firstname.lastname@example.org Citigate Dewe Rogerson David Dible/ Nina Enegren/ Sita Shah Tel: +44(0)207-638-95-71 email@example.com
SOURCE ThromboGenics NV
More by this Source
ThromboGenics Business Update
Nov 07, 2013, 13:04 ET
National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT), Including When Associated With Macular Hole
Oct 22, 2013, 20:00 ET
ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA
Oct 21, 2013, 01:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.